SARS-CoV-2 Subunit Virus-Like Vaccine Demonstrates High Safety Profile and Protective Efficacy: Preclinical Study
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Public health threat coming from a rapidly developing COVID-19 pandemic calls for developing safe and effective vaccines with innovative designs. This paper presents preclinical trial results of “Betuvax-CoV-2”, a vaccine developed as a subunit vaccine containing a recombinant RBD-Fc fusion protein and betulin-based spherical virus-like nanoparticles as an adjuvant (“Betuspheres”). The aim of the study was to demonstrate vaccine safety in mice, rats, and Chinchilla rabbits through acute, subchronic, and reproductive toxicity studies. Along with safety, the vaccine demonstrated protective efficacy through SARS-CoV-2-neutralizing antibody production in mice, rats, hamsters, rabbits, and primates (rhesus macaque), and lung damage and infection protection in hamsters and rhesus macaque model. Eventually, “Betuvax-CoV-2” was proved to confer superior efficacy and protection against the SARS-CoV-2 in preclinical studies. Based on the above results, the vaccine was enabled to enter clinical trials that are currently underway.
Article activity feed
-
SciScore for 10.1101/2022.05.18.492452: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: The animals were infected at the FGBU (Federal State Budgetary Institution) Central Research Institute No. 48 of the Russian Ministry of Defense, Sergiev Posad, Russia. Sex as a biological variable Reproductive toxicity in female rats: The reproductive toxicity of the vaccine was studied in female (n=60) and male (n=30) outbred rats. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Antibody titers were expressed as log base 2 (Log2). Log2suggested: NoneAn immunohistochemical study was performed to immunotype infiltrated cells in the lungs using antibodies against the … SciScore for 10.1101/2022.05.18.492452: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics Field Sample Permit: The animals were infected at the FGBU (Federal State Budgetary Institution) Central Research Institute No. 48 of the Russian Ministry of Defense, Sergiev Posad, Russia. Sex as a biological variable Reproductive toxicity in female rats: The reproductive toxicity of the vaccine was studied in female (n=60) and male (n=30) outbred rats. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Antibody titers were expressed as log base 2 (Log2). Log2suggested: NoneAn immunohistochemical study was performed to immunotype infiltrated cells in the lungs using antibodies against the T-lymphocyte marker (CD3 — Cell Marque, 103-R94, Rocklin, California, USA) and macrophages M2-phenotype (CD163 MsmAb — CD3suggested: NoneAntibodies against vascular endothelial cells (CD31 Mon. mouse – Cell Marque, JC-70, Rocklin, California, USA) were also used. CD31suggested: NoneFor immunohistochemical evaluation of the coronavirus proteins (S- and N-proteins), SARS-CoV2 spike (Genetex, GTX135356, Irvine, California, USA) and SARS-CoV2 nucleocapsid (Invitrogen, MA1-7404, Waltham, Massachusetts, USA) antibodies were used. GTX135356suggested: (GeneTex Cat# GTX135356, RRID:AB_2887482)SARS-CoV2 nucleocapsidsuggested: (HistoSure by Synaptic Systems Cat# HS-452 111BT, RRID:AB_2891263)Experimental Models: Cell Lines Sentences Resources The SARS-CoV-2 accumulation titer in the lungs was determined using the negative colonies method on the Vero C1008 cell culture. Vero C1008suggested: ECACC Cat# 85020206, RRID:CVCL_0574)Experimental Models: Organisms/Strains Sentences Resources Animals & Ethics Statement: BALB/c and C57BL/6 mice used in the study were obtained from the Stolbovaya branch of the FSBI SCBT FMBA (Scientific Center of Biomedical Technologies of Federal Medical and Biological Agency) of Russia. BALB/csuggested: NoneC57BL/6suggested: NoneC57/ black mice (n=22) were immunized intraperitoneally twice at a dose of 5 or 20 μg or 40 μg /animal (n=7 per group) or PBS (n=8) over a 21-day period. C57/suggested: NoneSoftware and Algorithms Sentences Resources Animal husbandry was compliant with each facility’s SOPs and sanitary and epidemiological rules SR 2.2.1.3218-14 “Sanitary and Epidemiological Requirements for the Device, Equipment and Maintenance of Experimental Biological Clinics Experimental Biologicalsuggested: NoneUsing a computer video system (IBM PC + microscope Leica DM 1000, Leica Camera, Wetzlar, Germany) and the ImageScope-M software package (Systems for Microscopy and Analysis, Moscow, Russia), the “airiness” parameter, specific area of the histological section occupied by air and free from infiltration or exudate from the alveolar space, was determined in a semi-automatic mode. ImageScope-Msuggested: NoneStatistical Analysis: The obtained data were analyzed with Microsoft Office Excel 2010 ( Microsoft Office Excelsuggested: (Microsoft Excel, RRID:SCR_016137)(Microsoft, Redmond, Washington, USA) and GraphPad Prism v6.01 software (GraphPad Software, San Diego, California, USA) for geometric mean, standard deviation, arithmetic mean, and standard errors. GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)GraphPadsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT05270954 Active, not recruiting Safety, Tolerability and Immunogenicity of Recombinant COVID… Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-